Lavipharm S.A. Logo

Lavipharm S.A.

Develops & distributes Rx/OTC medicines, supplements & cosmetics for key therapeutic areas.

LAVI | AT

Overview

Corporate Details

ISIN(s):
GRS246003008
LEI:
213800USC69CRPRGWJ15
Country:
Greece
Address:
AGIAS MARINAS STR, 19002 PAIANIA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Lavipharm S.A. is an integrated international healthcare company focused on the research, development, manufacturing, marketing, and distribution of pharmaceutical products. The company's portfolio includes prescription (Rx) and over-the-counter (OTC) medicines, as well as food supplements and cosmetics. Lavipharm provides innovative treatment options to healthcare professionals, concentrating on key therapeutic areas such as cardiology, neurology (CNS), urology, oncology, and chronic pain. The company manages the entire value chain, from initial research and development to commercial sales and distribution.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-07 11:56
Regulatory News Service
Ανακοίνωση Τροποποίησης προγράμματος stock options
Greek (modern) 4.8 MB
2025-09-18 19:39
Interim Report
Οικονομική έκθεση LAVIPHARM Α.Ε. (2025,Εξαμηνιαία,Ενοποιημένη)
Greek (modern) 2.2 MB
2025-09-18 16:50
Earnings Release
ΔΕΛΤΙO ΤΥΠΟΥ ΟΙΚΟΝΟΜΙΚΑ ΑΠΟΤΕΛΕΣΜΑΤΑ Α΄ ΕΞΑΜΗΝΟΥ 2025
Greek (modern) 156.3 KB
2025-09-18 16:50
Earnings Release
FINANCIAL RESULTS PRESS RELEASE FIRST HALF 2025
English 99.2 KB
2025-07-10 09:38
Registration Form
Έντυπο παροχής πληροφοριών Κανονισμού (ΕΕ) 2017/1129 (άρθρ. 1 παρ. 5 η’) αναφορ…
Greek (modern) 216.3 KB
2025-07-09 09:52
Share Issue/Capital Change
Έντυπο παροχής πληροφοριών Κανονισμού (ΕΕ) 2017/1129 (άρθρ. 1 παρ. 4 θ΄) αναφορ…
Greek (modern) 205.1 KB
2025-07-03 18:12
Notice of Dividend Amount
ΓΝΩΣΤΟΠΟΙΗΣΗ ΑΠΟΚΟΠΗΣ ΔΙΚΑΙΩΜΑΤΟΣ ΜΕΡΙΣΜΑΤΟΣ / ΠΛΗΡΩΜΗΣ ΜΕΡΙΣΜΑΤΟΣ/ ΠΡΟΜΕΡΙΣΜΑΤ…
Greek (modern) 555.0 KB
2025-07-03 18:00
Post-Annual General Meeting Information
ΔΕΛΤΙΟ ΤΥΠΟΥ ΓΕΝΙΚΗΣ ΣΥΝΕΛΕΥΣΗΣ
Greek (modern) 123.4 KB
2025-07-03 18:00
Post-Annual General Meeting Information
PRESS RELEASE
English 121.3 KB
2025-07-03 17:35
Post-Annual General Meeting Information
ΑΝΑΚΟΙΝΩΣΗ ΕΠΙΤΡΟΠΗΣ ΕΛΕΓΧΟΥ
Greek (modern) 503.0 KB
2025-07-03 17:17
Board/Management Information
ΓΝΩΣΤΟΠΟΙΗΣΗ ΑΛΛΑΓΗΣ ΣΥΝΘΕΣΗΣ ΔΙΟΙΚΗΤΙΚΟΥ ΣΥΜΒΟΥΛΙΟΥ
Greek (modern) 598.1 KB
2025-07-03 17:05
Post-Annual General Meeting Information
ΑΝΑΚΟΙΝΩΣΗ ΓΙΑ ΤΙΣ ΑΠΟΦΑΣΕΙΣ ΓΕΝΙΚΗΣ ΣΥΝΕΛΕΥΣΗΣ
Greek (modern) 195.1 KB
2025-06-11 16:30
Pre-Annual General Meeting Information
ΠΡΟΣΚΛΗΣΗ ΣΕ ΤΑΚΤΙΚΗ ΓΕΝΙΚΗ ΣΥΝΕΛΕΥΣΗ
Greek (modern) 191.0 KB
2025-05-15 16:19
Earnings Release
Βασικά Οικονομικά Μεγέθη A Τριμήνου 2025
Greek (modern) 118.2 KB
2025-05-15 16:19
Earnings Release
Financial Results Q1 2025
English 92.6 KB

Automate Your Workflow. Get a real-time feed of all Lavipharm S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Lavipharm S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Lavipharm S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Biotech firm using enzyme tech for pharma, healthcare, and bioprocess CDMO services.
South Korea
092040
AMICUS THERAPEUTICS, INC. Logo
Develops advanced therapies for rare lysosomal storage disorders.
United States of America
FOLD
AMINOLOGICS CO.,LTD. Logo
Manufactures high-purity chiral amino acids & APIs for pharma, chemical, and food industries.
South Korea
074430
Amneal Pharmaceuticals, Inc. Logo
Develops & commercializes essential medicines: generics, injectables & specialty drugs.
United States of America
AMRX
Amphastar Pharmaceuticals, Inc. Logo
Develops and manufactures complex injectable, intranasal, and inhalation pharmaceutical products.
United States of America
AMPH
Amylyx Pharmaceuticals, Inc. Logo
Developing novel therapies for neurodegenerative diseases like ALS and Wolfram syndrome.
United States of America
AMLX
AN2 Therapeutics, Inc. Logo
Developing novel small molecule drugs for infectious diseases and oncology using boron chemistry.
United States of America
ANTX
Develops approved cannabinoid medicines for pain, epilepsy, and heart failure.
United Kingdom
ANAN
ANAPTYSBIO, INC Logo
Clinical-stage biotech developing immunology therapies for autoimmune and inflammatory diseases.
United States of America
ANAB
Develops qPCR diagnostic kits and robotic automation systems for clinical and research laboratories.
Türkiye
ANGEN

Talk to a Data Expert

Have a question? We'll get back to you promptly.